EAM
XERS icon

Eagle Asset Management’s Xeris Biopharma Holdings XERS Stock Holding History

Eagle Asset Management’s Portfolio XERS Stock Details XERS Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q1 		– Sell
-20,423
Closed -$48K – 623
2023
Q4 		$48K Buy
+20,423
New +$37.7K ﹤0.01% 555

Other funds holding XERS

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
CC
Caxton Corporation Princeton, New Jersey $4.02M AUM 256.08% 1-Year Est. Return
MB
MPM BioImpact Boston, Massachusetts $1.29B AUM 141.72% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
RA
Rosalind Advisors Toronto, Ontario, Canada $249M AUM 80.12% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
N
Nuveen Charlotte, North Carolina $369B AUM 31.66% 1-Year Est. Return
CP
CenterBook Partners Greenwich, Connecticut $1.86B AUM 24.52% 1-Year Est. Return

Eagle Asset Management's XERS Position: Q1 2024 in Review

Eagle Asset Management sold out of Xeris Biopharma Holdings (XERS) in Q1 2024, closing a stake of 20,423 shares — an estimated $48K sold.

Eagle Asset Management first reported a position in XERS in Q4 2023 and held it in 1 quarter. The position peaked at $48K in Q4 2023. 143 funds tracked by Wall St. Rank hold XERS as of Q1 2024.

  • Eagle Asset Management reported no remaining Xeris Biopharma Holdings position as of Q1 2024 after selling out during the quarter.
  • Eagle Asset Management sold 20,423 Xeris Biopharma Holdings shares in Q1 2024, an estimated $48K.
  • Eagle Asset Management first reported a position in Xeris Biopharma Holdings in Q4 2023 and held it in 1 quarter.
  • Eagle Asset Management's Xeris Biopharma Holdings position peaked at $48K in Q4 2023.
  • 143 funds tracked by Wall St. Rank held Xeris Biopharma Holdings as of Q1 2024.

Based on Eagle Asset Management's 13F filing for Q1 2024, filed 9 May 2024.